US68572M1062 - Common Stock
ORCHESTRA BIOMED HOLDINGS IN
NASDAQ:OBIO (9/27/2023, 7:00:02 PM)
After market: 7.93 0 (0%)7.93
+0.04 (+0.51%)
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The Company’s flagship product candidates are Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of artery disease, the leading cause of mortality worldwide, and BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension, a significant risk factor for death worldwide. Virtue SAB is a drug/device combination product candidate for the treatment of artery disease designed to deliver an extended-release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant. BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.
ORCHESTRA BIOMED HOLDINGS IN
150 Union Square Drive
New Hope PENNSYLVANIA
P: 16463439298.0
Employees: 0
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
The company got approval from the FDA to go ahead with a pivotal study for a hypertension therapy.
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually...
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent...
Here you can normally see the latest stock twits on OBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: